Retatrutide vs Survodutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Also: BI 456906
A dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. | Survodutide activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). The glucagon component adds metabolic benefits beyond pure GLP-1 agonists. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | Limited community data available See research protocols |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Typical Duration | Long-term use expected | Long-term use expected |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 2 trials showed up to 24% weight loss at 48 weeks, the highest seen in any obesity drug trial. Studies demonstrate significant improvements in metabolic markers, liver fat reduction, and glycemic control. Phase 3 trials underway. | Phase 2 trials showed up to 19% weight loss at 46 weeks. Significant liver fat reduction makes it promising for NASH. Phase 3 trials ongoing for both obesity and NASH indications. |
Frequently Asked Questions: Retatrutide vs Survodutide
What is the difference between Retatrutide and Survodutide?
Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials. Survodutide is a weight loss peptide that a dual glp-1/glucagon receptor agonist in development for obesity and nash. combines appetite suppression with increased energy expenditure. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Survodutide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Survodutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Survodutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Survodutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Retatrutide and Survodutide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.